SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer

The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-week...

Descripción completa

Detalles Bibliográficos
Autores principales: Clamp, A R, Mäenpää, J, Cruickshank, D, Ledermann, J, Wilkinson, P M, Welch, R, Chan, S, Vasey, P, Sorbe, B, Hindley, A, Jayson, G C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361090/
https://www.ncbi.nlm.nih.gov/pubmed/16404360
http://dx.doi.org/10.1038/sj.bjc.6602910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361090/
https://www.ncbi.nlm.nih.gov/pubmed/16404360
http://dx.doi.org/10.1038/sj.bjc.6602910

Ejemplares similares